1
|
Lokaj B, Pugliese MT, Kinkel K, Lovis C, Schmid J. Barriers and facilitators of artificial intelligence conception and implementation for breast imaging diagnosis in clinical practice: a scoping review. Eur Radiol 2024; 34:2096-2109. [PMID: 37658895 PMCID: PMC10873444 DOI: 10.1007/s00330-023-10181-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 06/07/2023] [Accepted: 07/10/2023] [Indexed: 09/05/2023]
Abstract
OBJECTIVE Although artificial intelligence (AI) has demonstrated promise in enhancing breast cancer diagnosis, the implementation of AI algorithms in clinical practice encounters various barriers. This scoping review aims to identify these barriers and facilitators to highlight key considerations for developing and implementing AI solutions in breast cancer imaging. METHOD A literature search was conducted from 2012 to 2022 in six databases (PubMed, Web of Science, CINHAL, Embase, IEEE, and ArXiv). The articles were included if some barriers and/or facilitators in the conception or implementation of AI in breast clinical imaging were described. We excluded research only focusing on performance, or with data not acquired in a clinical radiology setup and not involving real patients. RESULTS A total of 107 articles were included. We identified six major barriers related to data (B1), black box and trust (B2), algorithms and conception (B3), evaluation and validation (B4), legal, ethical, and economic issues (B5), and education (B6), and five major facilitators covering data (F1), clinical impact (F2), algorithms and conception (F3), evaluation and validation (F4), and education (F5). CONCLUSION This scoping review highlighted the need to carefully design, deploy, and evaluate AI solutions in clinical practice, involving all stakeholders to yield improvement in healthcare. CLINICAL RELEVANCE STATEMENT The identification of barriers and facilitators with suggested solutions can guide and inform future research, and stakeholders to improve the design and implementation of AI for breast cancer detection in clinical practice. KEY POINTS • Six major identified barriers were related to data; black-box and trust; algorithms and conception; evaluation and validation; legal, ethical, and economic issues; and education. • Five major identified facilitators were related to data, clinical impact, algorithms and conception, evaluation and validation, and education. • Coordinated implication of all stakeholders is required to improve breast cancer diagnosis with AI.
Collapse
Affiliation(s)
- Belinda Lokaj
- Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Delémont, Switzerland.
- Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Division of Medical Information Sciences, Geneva University Hospitals, Geneva, Switzerland.
| | - Marie-Thérèse Pugliese
- Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Delémont, Switzerland
| | - Karen Kinkel
- Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland
| | - Christian Lovis
- Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Medical Information Sciences, Geneva University Hospitals, Geneva, Switzerland
| | - Jérôme Schmid
- Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Delémont, Switzerland
| |
Collapse
|
2
|
Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, Ock CY, Kim S. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. J Breast Cancer 2023; 26:405-435. [PMID: 37926067 PMCID: PMC10625863 DOI: 10.4048/jbc.2023.26.e45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 09/25/2023] [Accepted: 10/06/2023] [Indexed: 11/07/2023] Open
Abstract
Breast cancer is a significant cause of cancer-related mortality in women worldwide. Early and precise diagnosis is crucial, and clinical outcomes can be markedly enhanced. The rise of artificial intelligence (AI) has ushered in a new era, notably in image analysis, paving the way for major advancements in breast cancer diagnosis and individualized treatment regimens. In the diagnostic workflow for patients with breast cancer, the role of AI encompasses screening, diagnosis, staging, biomarker evaluation, prognostication, and therapeutic response prediction. Although its potential is immense, its complete integration into clinical practice is challenging. Particularly, these challenges include the imperatives for extensive clinical validation, model generalizability, navigating the "black-box" conundrum, and pragmatic considerations of embedding AI into everyday clinical environments. In this review, we comprehensively explored the diverse applications of AI in breast cancer care, underlining its transformative promise and existing impediments. In radiology, we specifically address AI in mammography, tomosynthesis, risk prediction models, and supplementary imaging methods, including magnetic resonance imaging and ultrasound. In pathology, our focus is on AI applications for pathologic diagnosis, evaluation of biomarkers, and predictions related to genetic alterations, treatment response, and prognosis in the context of breast cancer diagnosis and treatment. Our discussion underscores the transformative potential of AI in breast cancer management and emphasizes the importance of focused research to realize the full spectrum of benefits of AI in patient care.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Seokhwi Kim
- Department of Pathology, Ajou University School of Medicine, Suwon, Korea
- Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
| |
Collapse
|
3
|
van Nijnatten TJA, Payne NR, Hickman SE, Ashrafian H, Gilbert FJ. Overview of trials on artificial intelligence algorithms in breast cancer screening - A roadmap for international evaluation and implementation. Eur J Radiol 2023; 167:111087. [PMID: 37690352 DOI: 10.1016/j.ejrad.2023.111087] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/23/2023] [Accepted: 09/04/2023] [Indexed: 09/12/2023]
Abstract
Accumulating evidence from retrospective studies demonstrate at least non-inferior performance when using AI algorithms with different strategies versus double-reading in mammography screening. In addition, AI algorithms for mammography screening can reduce work load by moving to single human reading. Prospective trials are essential to avoid unintended adverse consequences before incorporation of AI algorithms into UK's National Health Service (NHS) Breast Screening Programme (BSP). A stakeholders' meeting was organized in Newnham College, Cambridge, UK to undertake a review of the current evidence to enable consensus discussion on next steps required before implementation into a screening programme. It was concluded that a multicentre multivendor testing platform study with opt-out consent is preferred. AI thresholds from different vendors should be determined while maintaining non-inferior screening performance results, particularly ensuring recall rates are not increased. Automatic recall of cases using an agreed high sensitivity AI score versus automatic rule out with a low AI score set at a high sensitivity could be used. A human reader should still be involved in decision making with AI-only recalls requiring human arbitration. Standalone AI algorithms used without prompting maintain unbiased screening reading performance, but reading with prompts should be tested prospectively and ideally provided for arbitration.
Collapse
Affiliation(s)
- T J A van Nijnatten
- Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Level 5, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands
| | - N R Payne
- Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Level 5, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom
| | - S E Hickman
- Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Level 5, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom; Department of Radiology, Barts Health NHS Trust, The Royal London Hospital, 80 Newark Street, London E1 2ES, United Kingdom
| | - H Ashrafian
- Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, St Mary's Hospital, London, United Kingdom
| | - F J Gilbert
- Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Level 5, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, United Kingdom.
| |
Collapse
|
4
|
Nabheerong P, Kiththiworaphongkich W, Cholamjiak W. Breast Cancer Screening Using a Modified Inertial Projective Algorithms for Split Feasibility Problems. Int J Breast Cancer 2023; 2023:2060375. [PMID: 37720822 PMCID: PMC10501843 DOI: 10.1155/2023/2060375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 07/30/2023] [Accepted: 08/17/2023] [Indexed: 09/19/2023] Open
Abstract
To detect breast cancer in mammography screening practice, we modify the inertial relaxed CQ algorithm with Mann's iteration for solving split feasibility problems in real Hilbert spaces to apply in an extreme learning machine as an optimizer. Weak convergence of the proposed algorithm is proved under certain mild conditions. Moreover, we present the advantage of our algorithm by comparing it with existing machine learning methods. The highest performance value of 85.03% accuracy, 82.56% precision, 87.65% recall, and 85.03% F1-score show that our algorithm performs better than the other machine learning models.
Collapse
Affiliation(s)
- Pennipat Nabheerong
- Radiology Department, School of Medicine, University of Phayao, Phayao 56000, Thailand
| | | | | |
Collapse
|
5
|
Oberije CJG, Sharma N, James JJ, Ng AY, Nash J, Kecskemethy PD. Comparing Prognostic Factors of Cancers Identified by Artificial Intelligence (AI) and Human Readers in Breast Cancer Screening. Cancers (Basel) 2023; 15:3069. [PMID: 37370680 DOI: 10.3390/cancers15123069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/25/2023] [Accepted: 06/02/2023] [Indexed: 06/29/2023] Open
Abstract
Invasiveness status, histological grade, lymph node stage, and tumour size are important prognostic factors for breast cancer survival. This evaluation aims to compare these features for cancers detected by AI and human readers using digital mammography. Women diagnosed with breast cancer between 2009 and 2019 from three UK double-reading sites were included in this retrospective cohort evaluation. Differences in prognostic features of cancers detected by AI and the first human reader (R1) were assessed using chi-square tests, with significance at p < 0.05. From 1718 screen-detected cancers (SDCs) and 293 interval cancers (ICs), AI flagged 85.9% and 31.7%, respectively. R1 detected 90.8% of SDCs and 7.2% of ICs. Of the screen-detected cancers detected by the AI, 82.5% had an invasive component, compared to 81.1% for R1 (p-0.374). For the ICs, this was 91.5% and 93.8% for AI and R1, respectively (p = 0.829). For the invasive tumours, no differences were found for histological grade, tumour size, or lymph node stage. The AI detected more ICs. In summary, no differences in prognostic factors were found comparing SDC and ICs identified by AI or human readers. These findings support a potential role for AI in the double-reading workflow.
Collapse
Affiliation(s)
- Cary J G Oberije
- Kheiron Medical Technologies, 112-116 Old St., London EC1V 9BG, UK
| | - Nisha Sharma
- Breast Screening Unit, Leeds Teaching Hospital NHS Trust, Leeds LS14 6UH, UK
| | - Jonathan J James
- Nottingham Breast Institute, City Hospital, Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK
| | - Annie Y Ng
- Kheiron Medical Technologies, 112-116 Old St., London EC1V 9BG, UK
| | - Jonathan Nash
- Kheiron Medical Technologies, 112-116 Old St., London EC1V 9BG, UK
| | | |
Collapse
|
6
|
Mumuni AN, Hasford F, Udeme NI, Dada MO, Awojoyogbe BO. A SWOT analysis of artificial intelligence in diagnostic imaging in the developing world: making a case for a paradigm shift. PHYSICAL SCIENCES REVIEWS 2022. [DOI: 10.1515/psr-2022-0121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Abstract
Diagnostic imaging (DI) refers to techniques and methods of creating images of the body’s internal parts and organs with or without the use of ionizing radiation, for purposes of diagnosing, monitoring and characterizing diseases. By default, DI equipment are technology based and in recent times, there has been widespread automation of DI operations in high-income countries while low and middle-income countries (LMICs) are yet to gain traction in automated DI. Advanced DI techniques employ artificial intelligence (AI) protocols to enable imaging equipment perceive data more accurately than humans do, and yet automatically or under expert evaluation, make clinical decisions such as diagnosis and characterization of diseases. In this narrative review, SWOT analysis is used to examine the strengths, weaknesses, opportunities and threats associated with the deployment of AI-based DI protocols in LMICs. Drawing from this analysis, a case is then made to justify the need for widespread AI applications in DI in resource-poor settings. Among other strengths discussed, AI-based DI systems could enhance accuracies in diagnosis, monitoring, characterization of diseases and offer efficient image acquisition, processing, segmentation and analysis procedures, but may have weaknesses regarding the need for big data, huge initial and maintenance costs, and inadequate technical expertise of professionals. They present opportunities for synthetic modality transfer, increased access to imaging services, and protocol optimization; and threats of input training data biases, lack of regulatory frameworks and perceived fear of job losses among DI professionals. The analysis showed that successful integration of AI in DI procedures could position LMICs towards achievement of universal health coverage by 2030/2035. LMICs will however have to learn from the experiences of advanced settings, train critical staff in relevant areas of AI and proceed to develop in-house AI systems with all relevant stakeholders onboard.
Collapse
Affiliation(s)
| | - Francis Hasford
- Department of Medical Physics , University of Ghana, Ghana Atomic Energy Commission , Accra , Ghana
| | | | | | | |
Collapse
|